USPTO serial 79338455
AUTOLUS
Reviewed by CopyMark Law Group
Reg. 7095476Status 404
- Filing date
- Status date
- Registration date
- Jul 4, 2023
- Examiner
- WEIGLE, KATHERINE CONNOLLY
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AUTOLUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical and veterinary preparations for therapeutic purposes, for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical preparations for cell therapy, for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical preparations for gene therapy, for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; medical preparations for the treatment of cancer; cells for medial or clinical use, namely cells featuring chimeric antigen receptors (CAR) and therapeutic preparations thereof, for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; antibodies for medical purposes for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors, namely, culture media for cultivating and augmentation of human and animal cells; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes | SECTION 70 - CANCELLED | — |
| 042 | Scientific and technological services and research and design relating thereto, namely medical research, scientific research, analysis and testing in the field of human and animal cell and gene therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell and gene therapies ; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services | SECTION 70 - CANCELLED | — |
| 044 | Medical services; veterinary services; medical and veterinary services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes namely, medical services relating to the removal, treatment and processing of human and animal cells; medical and veterinary services in the nature of reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Autolus Limited
- Other trademarks owned by Autolus Limited
- Other trademarks owned by Autolus Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AUTOLUS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 12, 2026 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Feb 12, 2026 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Nov 15, 2025 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Nov 15, 2025 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Oct 31, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 6, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 5, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 4, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 4, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 4, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 9, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 18, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 18, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 5, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 5, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 29, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 15, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 13, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 11, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 11, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 5, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 9, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 8, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 15, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 14, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 14, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 19, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 15, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 14, 2022 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |